Serafin, A., F. Angotzi, A. Bevilacqua, A. Cellini, M. D’antiga, L. Bonaldi, A. Martines, E. Albi, E. Sant’antonio, F. Martini, S. De Antoni, S. Pepe, I. Cavallari, A. Noto, A.M. Frustaci, F.R. Mauro, P. Ghia, L. Scarfò, L. Trentin, and A. Visentin. 2026. “P065 | Clinical and Genomic Patterns of Disease Progression in CLL Patients Treated With Fixed-Duration Versus Continuous Targeted Therapies: A. Serafin1, F. Angotzi1, A. Bevilacqua1, A. Cellini1, M. D’antiga1, L. Bonaldi2, A. Martines2, E. Albi3, E. Sant’antonio3, F. Martini3, S. De Antoni2, S. Pepe4, I. Cavallari2, A. Noto5, A.M. Frustaci5, F.R. Mauro4, P. Ghia3|6, L. Scarfò3|6, L. Trentin1, A. Visentin1 | 1Hematology Unit, Department of Medicine, University of Padova; 2Immunology and Molecular Oncology Unit, Veneto Institute of Oncology IOV-IRCSS; 3Strategic Research Program on CLL, IRCCS Ospedale San Raffaele; 4Hematology, Department of Translational and Precision Medicine, "Sapienza" University; 5Department of Hematology, ASST Grande Ospedale Metropolitano Niguarda; 6Medical School, Università Vita-Salute San Raffaele”. Haematologica 111 (s1). Pavia, Italy. https://doi.org/10.3324/haematol.2026.s1.130.